Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2020)

Vaxcyte's (PCVX) quarterly Gains from Investment Securities came in at $179000.0 in Q1 2020, up 79.0% on a QoQ basis from $100000.0 in Q3 2019.

Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2020) Analysis & Trends

Vaxcyte (PCVX) has 2 years of Gains from Investment Securities data on file, last reported at $179000.0 in Q1 2020.

On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $179000.0 in Q1 2020; TTM through Dec 2020 was $179000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $179000.0, up 1591.67% from the prior year.
Gains from Investment Securities for Q1 2020 stood at $179000.0, up from $100000.0 in the prior quarter.
Over the last five years, Gains from Investment Securities for PCVX reached as high as $179000.0 in Q1 2020 and fell as low as -$200000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vaxcyte	7.76 Bn	7.76 Bn	-

Download Data